News
-
May 1, 2013
Seaside Therapeutics to Announce Results from a Phase 2b Clinical Trial of Arbaclofen in Autism Spectrum Disorder at the International Meeting for Autism Research (IMFAR) 2013 Conference -
December 3, 2012
Autism Speaks awards $2 million grant to Delivering Scientific Innovation for Autism LLC (DELSIA) for partnership with Seaside Therapeutics to Develop Innovative Autism Treatments -
September 19, 2012
Seaside Therapeutics Publishes Seminal Research Supporting the Disease-Modifying Potential of STX209 for the Treatment of Fragile X Syndrome -
September 19, 2012
Seaside Therapeutics Named a “Fierce 15” Biotech Company for 2012 -
June 19, 2012
Roche and Seaside Therapeutics Announce Landmark Alliance to Advance Novel Treatments for Fragile X Syndrome and Autism Spectrum Disorders -
March 27, 2012
Seaside Therapeutics Announces Issuance of Key Patent for Lead Autism Candidate STX209 -
July 8, 2011
Seaside Therapeutics Presents Phase 2 Data Autism Spectrum Disorders at the 42nd Autism Society National Conference -
June 21, 2011
Seaside Therapeutics Initiates Phase 2b Study of STX209 in Autism Spectrum Disorders -
June 2, 2011
Seaside Therapeutics Initiates Pivotal Phase 3 Study of STX209 in Fragile X Syndrome -
May 18, 2011
Seaside Therapeutics Publishes Review of Advances in the Treatment of Fragile X Syndrome in American Chemical Society Chemical Neuroscience -
September 9, 2010
Seaside Therapeutics Reports Positive Data from Phase 2 Study of STX209 in Autism Spectrum Disorders -
July 26, 2010
Seaside Therapeutics Reports Data from Randomized, Placebo-Controlled Phase 2 Study in Fragile X Syndrome -
July 20, 2010
Seaside Therapeutics Appoints Leading Industry Executives to its Board of Directors